Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics
Abstract
Neuroendocrine tumors (TNEs) are defined as those neoplasms with a predominantly neuroendocrine cell differentiation, which can arise in most organs, although most are of gastrointestinal or pancreatic origin (≈65%). The Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE) groups tumors of the digestive tract and pancreas with the term gastroenteropancreatic neuroendocrine tumors (TNE-GEP). In general, they are tumors with a low incidence, between 1-7 new cases approximately per 100,000 inhabitants annually. The incidence, depending on the location of the primary tumor, is approximately 3.6 cases / 100,000 for TNE-GEPs, 1.5 cases / 100,000 for those of pulmonary origin and 0.8 cases / 100,000 for tumors of unknown origin. The incidence is slightly higher for men than for women, with an age at diagnosis around 50.
Keywords
Luteci oxodotreotida; Radiopharmaceutical; Gastroenteropancreatic neuroendocrine tumors
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics. Barcelona: Servei Català de la Salut; 2020.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/5674This item appears in following collections
The following license files are associated with this item: